TerminatedPhase 2

Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

Stopped: Insufficient enrollment rate

United States15 participantsStarted 2014-09

Plain-language summary

To investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of extranodal NK/T lymphoma, per WHO classification, 4th ed., which must include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1 immunostaining.
✓. a) Active Disease

Exclusion criteria

✕. CNS lymphoma.
✕. NK cell leukemia.
✕. Hemophagocytic lymphohistiocytosis.
✕. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).
✕. Use of systemic corticosteroids \>0.5 mg/kg/day within 10 days prior to obtaining 200 mL whole blood starting material.
✕. Patient is pregnant or lactating.
✕. Active second malignancy.
✕. Any prior allogeneic hematopoietic stem cell or solid organ transplant.

What they're measuring

Overall response rate

Timeframe: 1 year

Trial details

NCT IDNCT01948180

SponsorCell Medica Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-04-16

View on ClinicalTrials.gov More Lymphoma, Extranodal NK-T-Cell trials